期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 14, 期 2, 页码 127-135出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1744666X.2018.1427064
关键词
Systemic sclerosis; scleroderma; interstitial lung disease; staging; treatment pulmonary fibrosis; mycophenolate mofetil; cyclophosphamide; azathioprine; SLS; nintedanib; pirfenidone
类别
资金
- Versus Arthritis [20719] Funding Source: Medline
Introduction: Interstitial lung disease (ILD) is the most serious complication of systemic sclerosis (SSc). There is no accepted guidance as to which clinical, radiological or physiological thresholds should prompt initiation or changes in treatment. Furthermore, some patients with extensive disease remain stable without the need for intervention whilst others with limited disease at the outset, experience a precipitous decline.Areas covered: In this article, evidence for the integration of a number of disease-specific and patient-related domains are discussed and proposed. Introduction and maintenance of therapy requires a nuanced understanding of these factors and is crucial when weighing up the risks and benefits of immunomodulation. The evidence for the existing treatment modalities is discussed and the future directions for management of patients with SSc-ILD, which may include antifibrotic or biologic therapy, are explored.Expert commentary: In the management of SSc-ILD, a multidisciplinary team approach which integrates physiology and radiology with the patient at the centre of the process is crucial for effective management and provision of the best outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据